AI-Powered Tool Predicts CAR T Cell Therapy Outcomes for Lymphoma Patients

Breakthrough in Predicting CAR T Cell Therapy Outcomes

Researchers from City of Hope and Memorial Sloan Kettering (MSK) Cancer Center have developed a groundbreaking tool that utilizes machine learning to predict the effectiveness of chimeric antigen receptor (CAR) T cell therapy in non-Hodgkin lymphoma (NHL) patients. The study, published in Nature Medicine, introduces InflaMix (Inflammation Mixture Model), an innovative approach to assessing inflammation as a potential cause of CAR T failure 1

1

2

3

The Challenge of CAR T Cell Therapy

CAR T cell therapy has emerged as a promising treatment for blood cancers. However, more than half of NHL patients who don't respond to standard treatments also experience relapse or disease progression within six months of CAR T therapy. This new tool aims to address this challenge by predicting patient outcomes before treatment begins 1

1

2

3

How InflaMix Works

InflaMix was developed by analyzing blood biomarkers from 149 NHL patients. The machine learning model, an unsupervised artificial intelligence system, identified a unique inflammatory signature associated with a high risk of CAR T treatment failure, including increased risk of death or disease relapse 1

1

2

3

Dr. Marcel van den Brink, president of City of Hope Los Angeles and senior author of the paper, stated, "These studies demonstrate that by using machine learning and blood tests, we could develop a highly reliable tool that can help predict who will respond well to CAR T cell therapy" 1

1

Validation and Flexibility

The researchers validated their findings using three independent cohorts comprising 688 NHL patients with diverse clinical characteristics and disease subtypes. Importantly, the machine learning model demonstrated flexibility, performing well even when using only six commonly available blood tests typically evaluated for lymphoma patients 1

1

2

3

Dr. Sandeep Raj, lead author of the study, explained, "Our goal was to refine this concept and build a robust and reliable clinical tool that characterizes inflammation in the blood and predicts CAR T outcomes" 2

2

Related Stories

AI Tool SCORPIO Predicts Cancer Immunotherapy Response Using Routine Blood Tests

AI Tool Analyzes Bone Marrow Slides to Personalize Multiple Myeloma Treatment for Newly Diagnosed Patients

AI Tool Achieves 91% Accuracy Predicting Lung Cancer Immunotherapy Outcomes Across Global Study

AI analyzes tumor biopsies to predict immunotherapy success in rare cancers, quadrupling survival

Future Implications and Research

The development of InflaMix opens new avenues for personalized treatment strategies. Dr. Van den Brink noted, "InflaMix could be used to reliably identify patients who are about to be treated with CAR T and are at high risk for the treatment not working. By identifying these patients, doctors may be able to design new clinical trials that can boost the effectiveness of CAR T with additional treatment strategies" 1

1

3

Future research will focus on investigating whether blood inflammation defined by InflaMix directly influences CAR T cell function and exploring the source of this inflammation 1

1

2

3

Impact on Cancer Treatment

City of Hope, a leader in CAR T cell therapies, has treated over 1,700 patients since the late 1990s. The institution currently conducts about 70 ongoing clinical trials using immune cell products, primarily CAR T, for blood cancers and 15 different solid tumor types 1

1

2

This breakthrough in predictive medicine represents a significant step forward in the fight against blood cancers, potentially improving treatment outcomes and quality of life for NHL patients undergoing CAR T cell therapy.